
Last update at 2026-06-23T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Will PolyNovo’s (ASX:PNV) New Board Addition Shape Its U.S. Medtech Strategy?
Sun 19 Oct 25, 08:08 AMMedical Devices & Supplies - Specialty Stocks Q1 Highlights: Enovis (NYSE:ENOV)
Fri 16 May 25, 03:31 AMGlobus Medical Announces $500 Million Share Repurchase Program
Thu 15 May 25, 08:30 PMGMED Q1 Earnings & Revenues Miss, '25 EPS View Down, Stock Falls
Mon 12 May 25, 11:24 AMGlobus Medical, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Sun 11 May 25, 01:21 PMQ1 2025 Globus Medical Inc Earnings Call
Fri 09 May 25, 12:22 PMGlobus Medical Inc (GMED) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...
Fri 09 May 25, 07:39 AMGlobus Medical (GMED) Reports Q1 Earnings: What Key Metrics Have to Say
Thu 08 May 25, 10:30 PMGlobus Medical (GMED) Lags Q1 Earnings and Revenue Estimates
Thu 08 May 25, 09:45 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 609.90M | 120.72M | 165.39M | 243.02M | 180.41M |
| Minority interest | - | - | - | - | - |
| Net income | 537.90M | 102.98M | 122.87M | 190.17M | 149.19M |
| Selling general administrative | 1178.50M | 981.05M | 643.41M | 432.12M | 408.15M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1981.10M | 1483.88M | 1020.30M | 759.12M | 718.88M |
| Reconciled depreciation | 276.84M | 254.02M | 144.73M | 68.25M | 69.87M |
| Ebit | 609.90M | 219.70M | 201.85M | 227.95M | 171.95M |
| Ebitda | 729.90M | 473.73M | 346.58M | 313.82M | 289.05M |
| Depreciation and amortization | 120.00M | 254.02M | 144.73M | 85.87M | 117.10M |
| Non operating income net other | - | - | - | 15.07M | 8.45M |
| Operating income | 479.80M | 165.99M | 133.14M | 227.95M | 171.95M |
| Other operating expenses | 2459.10M | 2353.36M | 1435.33M | 786.59M | 763.24M |
| Interest expense | - | 4.19M | 20.13M | 14.23M | 9.30M |
| Tax provision | 67.20M | 17.74M | 42.52M | 52.85M | 31.22M |
| Interest income | - | - | - | - | - |
| Net interest income | 7.14M | -4.18900M | 20.13M | 14.23M | 9.30M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | 8.30M | 22.91M |
| Other items | - | - | - | - | - |
| Income tax expense | 72.00M | 17.74M | 42.52M | 52.85M | 31.22M |
| Total revenue | 2938.90M | 2519.36M | 1568.48M | 1022.84M | 958.10M |
| Total operating expenses | 1501.30M | 1317.88M | 887.16M | 522.87M | 524.02M |
| Cost of revenue | 957.80M | 1035.48M | 548.17M | 263.73M | 239.22M |
| Total other income expense net | 130.10M | -45.26900M | 32.25M | 15.07M | 8.45M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 537.87M | 102.98M | 122.87M | 190.17M | 149.19M |
| Net income applicable to common shares | - | - | - | 190.17M | 149.19M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 5302.76M | 5251.75M | 5086.08M | 2076.13M | 1957.26M |
| Intangible assets | 745.06M | 795.12M | 924.60M | 63.57M | 68.66M |
| Earning assets | - | - | - | - | - |
| Other current assets | 130.15M | 49.64M | 44.58M | 21.00M | 18.42M |
| Total liab | 729.51M | 1074.42M | 1088.12M | 229.75M | 215.88M |
| Total stockholder equity | 4573.25M | 4177.33M | 3997.96M | 1846.37M | 1741.39M |
| Deferred long term liab | - | - | - | 1.78M | 4.31M |
| Other current liab | 353.10M | 260.24M | 277.77M | 109.00M | 11.77M |
| Common stock | 0.14M | 0.14M | 0.14M | 0.10M | 0.10M |
| Capital stock | 0.14M | 0.14M | 0.14M | 0.10M | 0.10M |
| Retained earnings | 1387.96M | 1152.81M | 1137.27M | 1239.95M | 1194.27M |
| Other liab | - | - | - | 70.55M | 75.71M |
| Good will | 1435.03M | 1432.39M | 1434.54M | 197.47M | 179.71M |
| Other assets | - | - | - | 92.16M | 60.83M |
| Cash | 526.16M | 784.44M | 467.29M | 150.47M | 193.07M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 498.50M | 855.91M | 392.35M | 159.20M | 140.16M |
| Current deferred revenue | 27.66M | 22.14M | 18.37M | 14.10M | 12.03M |
| Net debt | -407.50000M | -247.25000M | 53.11M | -150.46600M | -193.06900M |
| Short term debt | 14.74M | 453.60M | 11.97M | - | 94.41M |
| Short long term debt | - | 443.35M | - | - | - |
| Short long term debt total | 118.66M | 537.19M | 520.40M | - | - |
| Other stockholder equity | 3169.81M | 3031.24M | 2870.75M | 630.95M | 553.79M |
| Property plant equipment | - | - | - | 243.73M | 221.08M |
| Total current assets | 2125.61M | 2177.26M | 1915.37M | 983.34M | 864.52M |
| Long term investments | 71.82M | 66.13M | 75.43M | 495.85M | 562.48M |
| Net tangible assets | - | - | - | 1585.33M | 1493.02M |
| Short term investments | 31.09M | 105.62M | 50.50M | 295.59M | 250.38M |
| Net receivables | 678.94M | 578.33M | 504.87M | 217.31M | 165.65M |
| Long term debt | - | - | 417.40M | - | - |
| Inventory | 759.28M | 659.23M | 848.13M | 298.98M | 237.00M |
| Accounts payable | 98.85M | 75.12M | 56.67M | 36.10M | 21.95M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 15.35M | -6.86100M | -10.19200M | -24.63000M | -6.77200M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.10M | 0.10M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | 1239.95M | 1194.27M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 150.60M | 75.10M | 78.59M | 43.31M | 36.33M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 3177.15M | 3074.49M | 3170.71M | 1092.78M | 1092.75M |
| Capital lease obligations | 118.66M | 93.84M | 103.00M | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 71.96M | -176.05100M | -78.13100M | -4.88000M | -284.55300M |
| Change to liabilities | - | - | - | 17.62M | 26.79M |
| Total cashflows from investing activities | -355.01400M | -176.05100M | 302.97M | -110.36200M | -375.93900M |
| Net borrowings | -449.98500M | 0.00000M | 0.00000M | - | - |
| Total cash from financing activities | -679.16000M | -27.69600M | -231.82100M | -109.96200M | 54.15M |
| Change to operating activities | - | - | - | -4.20500M | 11.72M |
| Net income | 537.87M | 102.98M | 122.87M | 190.17M | 149.19M |
| Change in cash | -258.28200M | 317.15M | 316.83M | -42.60300M | -46.32800M |
| Begin period cash flow | 784.44M | 467.29M | 150.47M | 193.07M | 239.40M |
| End period cash flow | 526.16M | 784.44M | 467.29M | 150.47M | 193.07M |
| Total cash from operating activities | 753.45M | 520.64M | 243.50M | 178.47M | 276.27M |
| Issuance of capital stock | - | - | - | - | 63.50M |
| Depreciation | 276.84M | 254.02M | 144.73M | 68.25M | 69.87M |
| Other cashflows from investing activities | -275.75400M | -44.15600M | - | -31.43500M | -34.48800M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -17.59800M | -29.86000M | -70.32800M | -61.74500M | -11.97100M |
| Change to account receivables | -52.18200M | -78.06200M | -49.91400M | -50.84300M | -25.89500M |
| Sale purchase of stock | -300.45100M | -85.78700M | -225.56200M | -144.49300M | 63.50M |
| Other cashflows from financing activities | -378.70900M | 58.09M | -6.25900M | -7.18500M | -9.34900M |
| Change to netincome | - | - | - | 22.57M | 71.90M |
| Capital expenditures | 164.68M | 115.43M | 78.27M | 74.05M | 56.90M |
| Change receivables | - | - | - | -50.84300M | -25.89500M |
| Cash flows other operating | - | - | - | -12.93900M | -6.38800M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | -41.85600M | -45.51800M |
| Change in working capital | -82.71200M | -97.55400M | -116.59800M | -105.26200M | -17.25200M |
| Stock based compensation | 49.78M | 54.19M | 52.74M | 32.81M | 30.59M |
| Other non cash items | -46.95500M | 332.89M | 97.54M | 14.72M | 61.50M |
| Free cash flow | 588.77M | 405.21M | 165.22M | 104.42M | 219.38M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GMED Globus Medical |
0.85 1.07% | 80.04 | 23.94 | 21.69 | 4.32 | 2.86 | 5.05 | 18.22 |
| ABT Abbott Laboratories |
2.70 3.07% | 90.53 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| SYK Stryker Corporation |
5.31 1.74% | 310.00 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
1.36 1.72% | 80.63 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
1.27 2.86% | 45.60 | 31.49 | 17.24 | 4.41 | 3.65 | 4.88 | 19.19 |
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
2560 General Armistead Avenue, Audubon, PA, United States, 19403-5214
| Name | Title | Year Born |
|---|---|---|
| Mr. David C. Paul | Co-Founder & Exec. Chairman | 1967 |
| Mr. Daniel T. Scavilla | Pres, CEO & Director | 1965 |
| Mr. Keith W. Pfeil | Sr. VP & CFO | 1979 |
| Ms. Kelly G. Huller Esq. | Sr. VP, Gen. Counsel & Sec. | 1972 |
| Mr. Brian J. Kearns | Sr. VP of Bus. Devel. & Investor Relations | 1967 |
| Mr. A. Brett Murphy | Exec. VP of International Sales | 1965 |
| Mr. Steven M. Payne | VP & Controller | 1971 |
| Mr. Mike Reeder | Exec. Officer | NA |
| Mr. Richard Holifield | Exec. Officer | NA |
| Mr. John Dowling | Exec. Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.